Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
aarmstrong
Wed, 02/02/2022 - 09:33
